mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Nature Medicine

Volumn 10, Issue 6, 2004, Pages 594-601

  Majumder, Pradip K ^a,b   Febbo, Phillip G ^a,b   Bikoff, Rachel ^a,b   Berger, Raanan ^a,b   Xue, Qi ^a,b   McMahon, Louis M ^c   Manolal, Judith ^a   Brugarolas, James ^a,b   J McDonnell, Timothy ^d   Golub, Todd R ^a,b,e   Loda, Massimo ^a,b   Lane, Heidi A ^c   Sellers, William R ^a,b,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN; GLYCOLYTIC ENZYME; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; REGULATOR PROTEIN; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; APOPTOSIS; CELL SURVIVAL; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOSUPPRESSIVE AGENTS; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENOTYPE; PLACEBOS; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSCRIPTION FACTORS;

ANIMALIA; MAMMALIA;

EID: 2942724235     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1052     Document Type: Article

References (50)

1. Maehama, T. & Dixon, J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273, 13375-13378 (1998).
2. del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. & Nunez, G. Interleulkin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687-689 (1997).
3. Kops, G.J. et al. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398, 630-634 (1999).
4. Nakamura, N. et al. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell. Biol. 20, 8969-8982 (2000).
5. Cross, D.A., Alessi, D.R., Cohen, P., Andjelkovich, M. & Hemmings, B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789 (1995).
6. Goberdhan, D.C., Paricio, N., Goodman, E.C., Mlodzik, M. & Wilson, C. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. 13, 3244-3258 (1999).
7. Oldham, S., Montagne, J., Radimerski, T., Thomas, G. & Hafen, E. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev. 14, 2689-2694 (2000).
8. Neshat, M.S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98, 10314-10319 (2001).
9. +/- mice. Proc. Natl. Acad. Sci. USA 98, 10320-10325 (2001).
10. Aoki, M., Blazek, E. & Vogt, P.K. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. USA 98, 136-141 (2001).
11. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J. & Cantley, L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10, 151-162 (2002).
12. Gao, X. et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 4, 699-704 (2002).
13. Gao, X. & Pan, D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 15, 1383-192 (2001).
14. Potter, C.J., Huang, H. & Xu, T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 105, 357-368 (2001).
15. Tee, A.R., Manning, B.D., Roux, P.P., Cantley, L.C. & Blenis, J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13, 1259-1268 (2003).
16. Huang, S. & Houghton, P.J. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr. Opin. Invest. Drugs 3, 295-304 (2002).
17. Majumder, P.K. et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc. Natl. Acad. Sci. USA 100, 7841-7846 (2003).
18. Nashan, B. Early clinical experience with a novel rapamycin derivative. Ther. Drug Monit. 24, 53-58 (2002).
19. Raught, B. et al. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J. 19, 434-444 (2000).
20. Bruckheimer, E.M. et al. The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo. Oncogene 19, 2404-2412 (2000).
21. Mootha, V.K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
22. Semenza, G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 64, 993-998 (2002).
23. Sellers, W.R. & Sawyers, C.A. Somatic genetics of prostate cancer: oncogenes and Tumor Suppressors. in Prostate Cancer Principles and Practice (ed. Kantoff, P.) (Lippincott Williams & Wilkins, Philadelphia, USA, 2002).
24. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
25. Shayesteh, L. et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21, 99-102 (1999).
26. Debnath, J. et al. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111, 29-40 (2002).
27. Debnath, J., Walker, S.J. & Brugge, J.S. Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J. Cell. Biol. 163, 315-326 (2003).
28. Wendel, H.G. et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332-337 (2004).
29. Edinger, A.L. & Thompson, C.B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13, 2276-2288 (2002).
30. McDonnell, T.J. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52, 6940-6944 (1992).
31. Furuya, Y., Krajewski, S., Epstein, J.I., Reed, J.C. & Isaacs, J.T. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin. Cancer Res. 2, 389-398 (1996).
32. Krajewska, M. et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 148, 1567-1576 (1996).
33. Colombel, M. et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol. 143, 390-400 (1993).
34. Baltaci, S., Orhan, D., Ozer, G., Tolunay, O. & Gogous, O. Bcl-2 proto-oncogene expression in low- and high-grade prostatic intraepithelial neoplasia. BJU Int. 85, 155-159 (2000).
35. McMenamin, M.E. et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59, 4291-4296 (1999).
36. Suzuki, H. et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58, 204-209 (1998).
37. Huang, H. et al. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem. 276, 38830-38836 (2001).
38. Mita, M.M., Mita, A. & Rowinsky, E.K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer 4, 126-137 (2003).
39. Hidalgo, M. & Rowinsky, E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680-6686 (2000).
40. Chi, K.N. et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin. Cancer Res. 7, 3920-3927 (2001).
41. Morris, M.J. et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 8, 679-683 (2002).
42. DiPaola, R.S. et al. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. J. Clin. Oncol. 17, 2213-2218 (1999).
43. Friedland, D. et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin. Oncol. 26, 19-23 (1999).
44. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732 (2003).
45. Abraham, R.T. mTOR as a positive regulator of tumor cell responses to hypoxia. Curr. Top. Microbiol. Immunol. 279, 299-319 (2004).
46. Hudson, C.C. et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22, 7004-7014 (2002).
47. Zhong, H. et al. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541-1545 (2000).
48. Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G.L. & Van Obberghen, E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277, 27975-27981 (2002).
49. Brugarolas, J.B., Vazquez, F., Reddy, A., Sellers, W.R. & Kaelin, W.G., Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4, 147-158 (2003).
50. Taesch, S. & Niese, D. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients. Transpl. Int. 7 (suppl. 1), S263-S266 (1994).